Piribo: It takes 600 million suffering in epidemic proportions for the smoke to clear!

Chronic Obstructive Pulmonary Disease (COPD) has been a much neglected area in drug development for several decades but now is the fifth leading cause of death worldwide.

Widely recognized as self-inflicted by smoking, COPD has often had low priority in respiratory programs. It is now realized that at least 600 million people, worldwide, suffer from COPD-numbers indicative of epidemic proportions. Governments, healthcare workers and pharmaceutical companies have recently prioritized and raised awareness of this disease area as one of major unmet medical need. Indicative of prioritization of this disease is the widespread occurrence of COPD-specific drug discovery in respiratory R&D in pharmaceutical companies. It is evident that a paradigm shift is taking place in COPD drug discovery. Rather than the traditional approach of symptom relief; new generation pharmaceuticals are beginning to target underlying disease.

COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease market analysis report seeks to provide background information on COPD, relevant drug targets, drug discovery strategies and associated therapeutics in current clinical development. This report examines the major classes of COPD therapeutics and discusses the approved and emerging COPD therapeutics. Buy this report to explore the therapeutic and market potential of select therapeutics and new research data compiled from an up-to-date survey.

“COPD Drug Discovery, How New Generation Therapies Seek to Target Underlying Disease” is available in hard copy and PDF format (via email or cd-rom) from Piribo. For more information go to: http://www.piribo.com/search/results.html?k=DMD072&x=3&y=14

Piribo Product ID: DMD072

About Piribo.
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,500 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.